|Bid||0.00 x 1100|
|Ask||0.00 x 1300|
|Day's Range||1,108.20 - 1,108.20|
|52 Week Range||834.04 - 1,114.10|
|PE Ratio (TTM)||327.97|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
For the quarter ending March 31, 2017, Abiomed (ABMD) reported revenues close to $124.7 million, which represents a YoY growth of about 30%.
Baxter International Inc and Claris Lifesciences Ltd have agreed to divest two types of pharmaceutical products to settle U.S. Federal Trade Commission charges that Baxter's proposed acquisition of Claris’ ...
Despite an upbeat guidance, lower cyclophosphamide sales are likely to mar Baxter International (BAX) performance in the second quarter 2017.